Cybin, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sumant Kulkarni from Canaccord Genuity maintained a Buy rating on the stock and has a $70.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sumant Kulkarni has given his Buy rating due to a combination of factors surrounding Cybin’s promising pipeline and upcoming milestones. The company is advancing its CYB003 program, a deuterated psilocin analog, which is in Phase 3 trials for major depressive disorder. The expectation of reporting top-line data from these trials in the coming years and the potential filing of a new drug application by the end of 2027 are significant catalysts for the stock.
Furthermore, Cybin’s CYB004, a deuterated DMT, is in Phase 2 trials for generalized anxiety disorder, with data expected in 2025. Although the valuation does not currently account for CYB004, the progress in CYB003 and the substantial market opportunity in treating major depressive disorder provide a strong basis for the Buy rating. The analyst’s confidence is bolstered by encouraging Phase 2 results and the anticipation of key data releases, which could drive the stock’s performance.